Dose-intense etoposide-cyclophosphamide without stem cell transplantation for patients with intermediate and high cytogenetic risk primary refractory and relapsed acute myeloid leukemia

Steven Trifilio; Zheng Zhou; Jessica Altman; Olga Frankfurt; Mihaela Pantiru; Jayesh Mehta

doi:10.1016/j.leukres.2013.05.006

Dose-intense etoposide-cyclophosphamide without stem cell transplantation for patients with intermediate and high cytogenetic risk primary refractory and relapsed acute myeloid leukemia

Steven Trifilio^*, Zheng Zhou, Jessica Altman, Olga Frankfurt, Mihaela Pantiru, Jayesh Mehta

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article

7 Scopus citations

Abstract

Dose-intense etoposide-cyclophosphamide (D-I ECy) without stem cell transplantation has been used in salvage regimens for the treatment of resistant acute myeloid leukemia(AML). Previous D-I ECy studies classified AML according to FAB-criteria, before cytogenetic risk was found to be a major determinant of prognosis. Currently the influence of karyotype on response to D-I ECy is unknown. Thus, an observational study was conducted in thirty four patients treated with D-I ECy for resistant AML. The results show this regimen is moderately effective in achieving CR in relapsed AML patients, including those with age >60 and poor cytogenetic risk category.

Original language	English (US)
Pages (from-to)	872-876
Number of pages	5
Journal	Leukemia Research
Volume	37
Issue number	8
DOIs	https://doi.org/10.1016/j.leukres.2013.05.006
State	Published - Aug 2013

Keywords

Acute myeloid leukemia
Complete remission
Cyclophosphamide
Etoposide

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.leukres.2013.05.006

Fingerprint Dive into the research topics of 'Dose-intense etoposide-cyclophosphamide without stem cell transplantation for patients with intermediate and high cytogenetic risk primary refractory and relapsed acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this

@article{bb063402531c4927a8bd13289e00685f,

title = "Dose-intense etoposide-cyclophosphamide without stem cell transplantation for patients with intermediate and high cytogenetic risk primary refractory and relapsed acute myeloid leukemia",

abstract = "Dose-intense etoposide-cyclophosphamide (D-I ECy) without stem cell transplantation has been used in salvage regimens for the treatment of resistant acute myeloid leukemia(AML). Previous D-I ECy studies classified AML according to FAB-criteria, before cytogenetic risk was found to be a major determinant of prognosis. Currently the influence of karyotype on response to D-I ECy is unknown. Thus, an observational study was conducted in thirty four patients treated with D-I ECy for resistant AML. The results show this regimen is moderately effective in achieving CR in relapsed AML patients, including those with age >60 and poor cytogenetic risk category.",

keywords = "Acute myeloid leukemia, Complete remission, Cyclophosphamide, Etoposide",

author = "Steven Trifilio and Zheng Zhou and Jessica Altman and Olga Frankfurt and Mihaela Pantiru and Jayesh Mehta",

year = "2013",

month = aug,

doi = "10.1016/j.leukres.2013.05.006",

language = "English (US)",

volume = "37",

pages = "872--876",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "8",

}

Dose-intense etoposide-cyclophosphamide without stem cell transplantation for patients with intermediate and high cytogenetic risk primary refractory and relapsed acute myeloid leukemia. / Trifilio, Steven; Zhou, Zheng; Altman, Jessica ; Frankfurt, Olga; Pantiru, Mihaela; Mehta, Jayesh.

In: Leukemia Research, Vol. 37, No. 8, 08.2013, p. 872-876.

Research output: Contribution to journal › Article

TY - JOUR

T1 - Dose-intense etoposide-cyclophosphamide without stem cell transplantation for patients with intermediate and high cytogenetic risk primary refractory and relapsed acute myeloid leukemia

AU - Trifilio, Steven

AU - Zhou, Zheng

AU - Altman, Jessica

AU - Frankfurt, Olga

AU - Pantiru, Mihaela

AU - Mehta, Jayesh

PY - 2013/8

Y1 - 2013/8

N2 - Dose-intense etoposide-cyclophosphamide (D-I ECy) without stem cell transplantation has been used in salvage regimens for the treatment of resistant acute myeloid leukemia(AML). Previous D-I ECy studies classified AML according to FAB-criteria, before cytogenetic risk was found to be a major determinant of prognosis. Currently the influence of karyotype on response to D-I ECy is unknown. Thus, an observational study was conducted in thirty four patients treated with D-I ECy for resistant AML. The results show this regimen is moderately effective in achieving CR in relapsed AML patients, including those with age >60 and poor cytogenetic risk category.

AB - Dose-intense etoposide-cyclophosphamide (D-I ECy) without stem cell transplantation has been used in salvage regimens for the treatment of resistant acute myeloid leukemia(AML). Previous D-I ECy studies classified AML according to FAB-criteria, before cytogenetic risk was found to be a major determinant of prognosis. Currently the influence of karyotype on response to D-I ECy is unknown. Thus, an observational study was conducted in thirty four patients treated with D-I ECy for resistant AML. The results show this regimen is moderately effective in achieving CR in relapsed AML patients, including those with age >60 and poor cytogenetic risk category.

KW - Acute myeloid leukemia

KW - Complete remission

KW - Cyclophosphamide

KW - Etoposide

UR - http://www.scopus.com/inward/record.url?scp=84879780788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879780788&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2013.05.006

DO - 10.1016/j.leukres.2013.05.006

M3 - Article

C2 - 23759246

AN - SCOPUS:84879780788

VL - 37

SP - 872

EP - 876

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 8

ER -